Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences' stock price has been impacted by several events over the past six months. The company reported its Q3 2025 earnings, posting an EPS of -$0.29, which exceeded analysts' expectations. The stock rose after the company presented promising data from its nPulse Cardiac Catheter System first-in-human feasibility study at the AF Symposium. As of February 6, 2026, the stock price gained 51.57% on the last trading day, rising from $13.69 to $20.75. Mizuho set a $30.00 price target, while Weiss Ratings reiterated a "sell (d-)" rating, and the consensus rating from analysts is "Hold" with an average target price of $26.00.

There is no explicit information available in the provided search results regarding demand seasonality for Pulse Biosciences, Inc.'s products and services.

Pulse Biosciences, Inc. is a bioelectric medicine company focused on health innovation through its CellFX System, which utilizes Nano-Pulse Stimulation (NPS) technology to clear dysfunctional cells while preserving surrounding tissue. The CellFX System is a Nanosecond Pulsed-Field Ablation (nsPFA) delivery platform primarily used to treat benign lesions of the skin. The CellFX nsPFA Percutaneous Electrode system is designed for soft tissue ablation in a surgical setting. The CellFX nsPFA Cardiac Clamp is intended for use in the surgical treatment of atrial fibrillation (AF). The CellFX nsPFA 360° Cardiac Catheter is designed to provide circumferential ablation in a single treatment cycle for atrial fibrillation. The CellFX Consol is a tunable, software-enabled, console-based platform that accommodates physicians' clinical workflow. The company is exploring the potential of its NPS platform in other medical specialties. Pulse Biosciences was founded in 2014 and was formerly known as Electroblate, Inc.

Pulse Biosciences generates substantial revenue from North America, particularly the United States. The company operates in North America and Europe. While it was founded in Miami, FL, its corporate headquarters are located in Hayward, CA.

Pulse Biosciences has demonstrated strong investor confidence, with an impressive 141.88% return as of May 2025. The company's innovative efforts in nanosecond pulse field ablation technology and strategic expansion plans have been focal points. Pulse Biosciences has received a consensus "Hold" rating from analysts, with an average rating score of 2.33. The company scored higher than 48% of companies evaluated by MarketBeat in the medical sector, ranking 580th out of 872 stocks. No specific events negatively impacted Pulse Biosciences' brand reputation in the past year were found in the provided search results.

Pulse Biosciences, Inc. has 176 institutional owners and shareholders holding a total of 6,931,377 shares. Major Institutional Owners include BlackRock, Inc., Vanguard Group Inc, Bank Of America Corp /de/, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, IWM - iShares Russell 2000 ETF, State Street Corp, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Griffin Asset Management, Inc., and Northern Trust Corp. Robert Duggan is a significant individual owner, holding the most shares of Pulse Biosciences. Approximately 0.85% to 3.16% of the company's stock is held by institutional investors, 73.58% by insiders, and 20.54% by retail investors.